Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.
about
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerThe Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-AnalysisRelevance of tumor-infiltrating lymphocytes in breast cancerThe Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and TreatmentInduction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective studyIntegration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.Modeling disease progression using dynamics of pathway connectivity.Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.Molecular characterization and targeted therapeutic approaches in breast cancerGranulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastasesTumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinomaClinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysisTumor-Associated Glycans and Immune SurveillanceTumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer.Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancerPrognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women.An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.Conservation of immune gene signatures in solid tumors and prognostic implications.Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response.Basal-like breast cancer: molecular profiles, clinical features and survival outcomesPredictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.New Method for Joint Network Analysis Reveals Common and Different Coexpression Patterns among Genes and Proteins in Breast CancerActivation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancerTumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study.
P2860
Q26745444-4464DFF0-926F-46CC-BEFE-64643503FDBCQ26745446-8F485652-64B7-44C0-8A9B-68BBA1735766Q26748691-B309ADB6-576C-49C4-BD78-593DE46765F2Q26795598-68CAF443-2B0E-4C23-8D3E-9C5E821CA4F5Q26865458-4A4ECF4B-CB46-4391-91FE-999183C27306Q28538654-752A615F-C3F4-4392-A18E-1FF5368753ABQ31034941-212F6DE7-59D3-44D2-B20F-EDE7964C9E6BQ33554629-6E97C6A7-2737-40F3-82E9-3E9F46A1D69FQ33717226-1F765EDF-17B8-48F0-AD2C-6AE191FAA3BFQ33827053-50729EFC-B17C-43A1-885B-D9A30D665F3DQ33960985-036392E2-B514-4E40-8130-7F59F3C22705Q34048222-E6DD13FC-669F-47F4-9009-D6D002E7EE82Q34447829-CB9FA0B2-6216-45E0-939C-5998AB838222Q34558758-B3FBAA48-AD24-42A4-8FE2-B1C2EF2B85C1Q34690824-EAC513B0-9417-4105-BD9B-04E14902DBBCQ34918110-50C229E1-0885-4C29-AFBC-78FD29B98BBFQ35000651-8C5CF523-4857-44E0-994C-EE2BEC523562Q35009369-57AC76AF-3297-46AE-AF2B-508F60037DA3Q35091690-D55ABBF2-BB9F-49C2-B5E3-A1FA73C90F56Q35218182-1F051AD2-66F6-4D1D-8B1F-FCF8A5C5EA1CQ35314135-668B2F3E-48B0-42BB-97AB-F556240D4221Q35425222-E2ED661A-E4EF-455A-9C31-54D29B460B75Q35530143-7EE2D4AE-89E6-4F8B-AED4-D41DA799DD83Q35549911-18795924-67CB-4D25-84FF-02ACE2C3B74EQ35798941-C16D65F6-3438-40A0-89D5-E9FB08CC8511Q35811294-854CCFCE-0A76-4E17-9DFB-F63C79EBAC34Q35890610-C597C602-C15E-4075-813B-B54B4C5987A1Q35929864-204DD7DB-0CEF-43B0-BF1B-50D4C6CF237CQ35992815-378A4565-5F63-4D42-A249-69099DD1F035Q36030405-75F27AB7-99DB-4004-96E2-F6592333EABBQ36050289-534AAF5A-DB2C-4BCB-84D0-542A92EE4480Q36085118-C4D65E2C-B31E-4760-A701-91615883619BQ36200301-9D2D02A6-CB70-4BCE-BD7D-450A3A087360Q36307206-2F68CBAE-9F9F-4A7A-A1BF-D3C83492CA0BQ36325873-8312B709-77EB-4B70-9C61-8C6F372E9CB4Q36637292-9D8D3BAD-4873-4FA1-B156-1C76BDE1AC48Q36661918-3988B030-F983-44A7-9E4C-7C6B8C5D3045Q36750699-61A257A4-B371-4E5A-8131-453BCC8EEC62Q36782680-F910C38F-71B6-461D-B9C3-21E75DB711ADQ36992949-A5B0CEAF-F412-43D4-BDB5-56FCF705EFAA
P2860
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular pathways: involvemen ...... and outcome in breast cancer.
@en
type
label
Molecular pathways: involvemen ...... and outcome in breast cancer.
@en
prefLabel
Molecular pathways: involvemen ...... and outcome in breast cancer.
@en
P50
P1476
Molecular pathways: involvemen ...... e and outcome in breast cancer
@en
P2093
Christos Sotiriou
Peter Dubsky
P356
10.1158/1078-0432.CCR-11-2701
P407
P577
2012-12-20T00:00:00Z